Adult attention deficit hyperactivity disorder
Adult attention deficit hyperactivity disorder is the psychiatric condition of attention deficit hyperactivity disorder (ADHD) in adults. About one-third to two-thirds of children with symptoms from early childhood continue to demonstrate ADHD symptoms throughout life.(p44)
|Adult attention deficit hyperactivity disorder|
|Other names||Adult ADHD, adult with ADHD, ADHD in adults, AADD|
|PET scan comparing levels of brain activity between subjects. Left: cerebral glucose metabolism in neurotypical subject. Right: observed decrease in cerebral glucose metabolism in ADHD subject.|
Three types of ADHD are identified in the DSM-5 as:
- Predominantly Inattentive Type (ADHD-PI or ADHD-I)
- Predominantly Hyperactive or Hyperactive-Impulsive Type (ADHD-PH or ADHD-HI)
- Combined Type (ADHD-C)
In later life, the hyperactive/impulsive subtype manifests less frequently.(p44) The hyperactivity symptoms tend to turn more into "inner restlessness", starting in adolescence and carrying on in adulthood.
Adult ADHD is typically marked by inattention and hyperfocus, hyperactivity (often internalised as restlessness), emotional dysregulation, and excessive mind wandering. Specifically, adults with ADHD present with persistent difficulties in following directions, remembering information, concentrating, organizing tasks, completing work within specified time frames and appearing timely in appointments. These difficulties affect several different areas of an ADHD adult's life, causing emotional, social, vocational, marital, legal, financial and/or academic problems. As a result, low self-esteem is commonly developed. However, given the right guidance and coaching, these traits of ADHD could also lead to career success.
Diagnosis follows one or several assessments which may include examination of personal history, observational evidence from family members or friends, academic reports, often going back to school years, as well as evaluation to diagnose additional possible conditions which often coexist with ADHD, called comorbidities or comorbid disorders.
The condition often runs in families, and while its exact causes are not fully known, genetic or environmental factors are understood to play a part. ADHD often - but not always - is a childhood-onset condition. Children under treatment will migrate to adult health services if necessary as they transit into adulthood, however diagnosis of adults involves full examination of their history.
Treatment of ADHD is usually based on a combination of behavioral interventions and medication. Exercise, sufficient sleep and nutritious food are also known to have a positive effect. Within school and work, reasonable accommodations may be put in place by structuring work tasks and setting up clear rules and limits for tasks.
The DSM-5, or Diagnostic and Statistical Manual of Mental Disorders, 2013 edition, defines three types of ADHD:
- a Predominantly Inattentive presentation
- a Predominantly Hyperactive-Impulsive presentation
- a Combined Type, that displays symptoms from both presentation
To meet the diagnostic criteria of ADHD, an individual must display:
- at least six inattentive-type symptoms for the inattentive type
- at least six hyperactive-type symptoms for the hyperactive-impulsive type
- all of the above to have the combined type
The symptoms (see below) were required to have been present since before the individual was seven years old, and must have interfered with at least two spheres of his or her functioning (at home and at school or work, for example) over the last six months. The DSM-IV criteria for ADHD were, however, tailored towards the type of symptoms that children would show, and might therefore have underestimated the prevalence of ADHD in adults.[page needed] In 2013, the newer DSM-5 reviewed some of these criteria, with more lenient requirements for the diagnosis, especially in adults, and the age limit for symptoms first arising raised to twelve years.
Signs and symptomsEdit
ADHD is a chronic condition, beginning in early childhood that can persist throughout a person's lifetime. It is estimated that 33–66% of children with ADHD will continue to have significant ADHD-related symptoms persisting into adulthood, resulting in a significant impact on education, employment, and interpersonal relationships.
Individuals with ADHD exhibit deficiencies in self-regulation and self-motivation which in turn foster problematic characteristics such as distractibility, procrastination and disorganization. They are often perceived by others as chaotic, with a tendency to need high stimulation to be less distracted and function effectively. The learning potential and overall intelligence of an adult with ADHD, however, is no different from the potential and intelligence of adults who do not have the disorder.
Whereas teachers and caregivers responsible for children are often attuned to the symptoms of ADHD, employers and others who interact with adults are less likely to regard such behaviors as a symptom. In part, this is because symptoms do change with maturity; adults who have ADHD are less likely to exhibit obvious hyperactive behaviors. Instead, they may report constant mental activity and inner restlessness as their hyperactivity internalizes.
Symptoms of ADHD (see table below) can vary widely between individuals and throughout the lifetime of an individual. As the neurobiology of ADHD is becoming increasingly understood, it is becoming evident that difficulties exhibited by individuals with ADHD are due to problems with the parts of the brain responsible for executive functions (see below: Pathophysiology). These result in problems with sustaining attention, planning, organization, prioritization, time blindness, impulse control and decision making.
The difficulties generated by these deficiencies can range from moderate to extreme, resulting in the inability to effectively structure their lives, plan daily tasks, or think of and act accordingly even when aware of potential consequences. These can lead to poor performance in school and work and can be followed by underachievement in these areas. In young adults, poor driving records with traffic violations as well as histories of substance use disorders may surface. The difficulty is often due to the ADHD person's observed behaviour (e.g. the impulsive types, who may insult their boss for instance, resulting in dismissal), despite genuinely trying to avoid these and knowing that it can get them in trouble. Often, the ADHD person will miss things that an adult of similar age and experience should catch onto or know. These lapses can lead others to label the individuals with ADHD as "lazy" or "stupid" or "inconsiderate".
As problems accumulate, a negativistic self-view becomes established and a vicious circle of failure is set up. Up to 80% of adults may have some form of psychiatric comorbidity such as depression or anxiety. Many with ADHD also have associated learning disabilities, such as dyslexia, which contributes to their difficulties.
Studies on adults with ADHD have shown that, more often than not, they experience self stigma and depression in childhood, commonly resulting from feeling neglected and different from their peers. These problems may play a role in the high levels of depression, substance abuse, and relationship problems that affect adults with ADHD later in life.
|Inattentive-type (ADHD-PI)||Hyperactive/impulsive-type (ADHD-PH)|
Over the last 30 years, research into ADHD has greatly increased. There is no single, unified theory that explains the cause of ADHD. Genetic factors are presumed important, and it has been suggested that environmental factors may affect how symptoms manifest.
It is becoming increasingly accepted that individuals with ADHD have difficulty with "executive functioning". In higher organisms, such as humans, these functions are thought to reside in the frontal lobes. They enable recall of tasks that need accomplishing, organization to accomplish these tasks, assessment of consequences of actions, prioritization of thoughts and actions, keeping track of time, awareness of interactions with surroundings, the ability to focus despite competing stimuli, and adaptation to changing situations.
Several lines of research based on structural and/or functional imaging techniques, stimulant drugs, psychological interventions have identified alterations in the dopaminergic and adrenergic pathways of individuals with ADHD. In particular, areas of the prefrontal cortex appear to be the most affected. Dopamine and norepinephrine are neurotransmitters which play an important role in brain function. The uptake transporters for dopamine and norepinephrine are overly active and clear these neurotransmitters from the synapse a lot faster than in normal individuals. This is thought to increase processing latency and salience, and diminished working memory.[non-primary source needed]
While there is no single medical, physical, or genetic test for ADHD an evaluation can be provided by a qualified mental health care professional or physician who gathers information from multiple sources. These can include ADHD symptom checklists, standardized behavior rating scales, a detailed history of past and current functions including the person's history of childhood behavior and school experiences, and information obtained from family members, friends, or significant others. The evaluations also seek to rule out other conditions or differential diagnoses such as depression, anxiety, or substance use disorders. Other diseases such as hyperthyroidism may exhibit symptoms similar to those of ADHD, and it is imperative to rule these out as well. Autism is sometimes mistaken for ADHD, due to impairments in executive functioning found in some people with autism. However, autism also typically involves difficulties in social interaction, restricted and repetitive patterns of behavior and interests, and problems with sensory processing, including hypersensitivity. Along with this, the quality of diagnosing an adult with ADHD can often be skewed being that the majority of adults with ADHD also have other complications, ranging from anxiety and depression to substance abuse.
Assessment of adult patients seeking a possible diagnosis can be better than in children due to the adult's greater ability to provide their own history, input, and insight. However, it has been noted that many individuals, particularly those with high intelligence, develop coping strategies that mask ADHD impairments and therefore they do not seek diagnosis and treatment.[unreliable medical source?]
Formal tests and assessment instruments such as IQ tests, standardized achievement tests, or neuropsychological tests typically are not helpful for identifying people with ADHD. Furthermore, no currently available physiological or medical measure is definitive diagnostically. However, psycho-educational and medical tests are helpful in ruling in or out other conditions (e.g. learning disabilities, allergies) that may be associated with ADHD-like behaviors.
United States medical and mental health professionals follow the Diagnostic and Statistical Manual of Mental Disorders (DSM) of the American Psychiatric Association; the International Classification of Diseases (ICD) published by the World Health Organisation (WHO) is often used by health professionals elsewhere. Periodic updates incorporate changes in knowledge and treatments.[unreliable medical source] For example, under DSM-IV (published in 1994, with corrections and minor changes in 2000), the diagnostic criteria for ADHD in adults broadly follow the same as in children, but the proposed revision for the DSM-5 differentiates the presentation of ADHD for children and adults for several symptoms.
Until recently ADHD in adults was considered as a continuation of child-onset ADHD. It is now established, however, that also an adult-onset version exists. In a large longitudinal study from 2015 it was found that 28 of the 31 persons who had an ADHD-diagnosis at the age of 38 never had received an ADHD-diagnosis when tested at the ages of 11, 13 and 15.
Suggested treatment for adult ADHD is to include a combined approach of psychosocial interventions (behavioural or cognitive), medication, vocational interventions, and regular follow-up support. Treatment often begins with medication selected to address the symptoms of ADHD, along with any comorbid conditions that may be present. Medication alone, while sometimes effective in correcting the physiological symptoms of ADHD, will not address the paucity of skills which many adults will have failed to acquire because of their ADHD (e.g., one might regain ability to focus with medication, but skills such as organizing, prioritizing and effectively communicating have taken others time to cultivate).
Medications to help treat ADHD include psychostimulants and non-stimulants. Guidelines and availability of the different options available for medication may vary depending on what country the person lives in.
Amphetamine and its derivatives, prototype stimulants, are available in immediate and long-acting formulations. Amphetamines act by multiple mechanisms including reuptake inhibition, displacement of transmitters from vesicles, reversal of uptake transporters and reversible MAO inhibition. Thus amphetamines actively increases the release of these neurotransmitters into the synaptic cleft. In the short term, methylphenidate, a benzylpiperidine and phenethylamine derivative stimulant medication, is well tolerated. However, long-term studies have not been conducted in adults and concerns about increases in blood pressure have not been established. Methylphenidate increases concentrations of dopamine and norepinephrine in the synaptic cleft, promoting increased neurotransmission. It acts to block the dopamine and norepinephrine reuptake transporters, thus slowing the removal at which these neurotransmitters are cleared from the synapses. Dextroamphetamine is a short-acting amphetamine.
In the UK, clinical guidelines recommend that psychostimulants are used as a first-line treatment. For people who cannot be treated with stimulants due to a substance use disorder or other contraindications, atomoxetine is the suggested first line treatment in the UK. In Canada, clinical guidelines suggest that first line treatment be methylphenidate or lisdexamfetamine. Second-line treatment in Canada includes atomoxetine or methylphenidate.
The non-stimulant atomoxetine (Strattera), may be an effective treatment for adult ADHD. Although atomoxetine has a half life similar to stimulants it exhibits delayed onset of therapeutic effects similar to antidepressants. Unlike the stimulants which are controlled substances, atomoxetine lacks addictive potential. It is particularly effective for those with the predominantly inattentive concentration type of attention deficit due to being primarily a norepinephrine reuptake inhibitor. It is often prescribed in adults who cannot tolerate the side effects of amphetamines or methylphenidate. It is also approved for ADHD by the US Food and Drug Administration. A rare but potentially severe side effect includes liver damage and increased suicidal ideation.
Bupropion and desipramine are two antidepressants that have demonstrated some evidence of effectiveness in the management of ADHD particularly when there is comorbid major depression, although antidepressants have lower treatment effect sizes.
Psychotherapy, including behavioral therapy, can help an adult with ADHD monitor his or her own behavior and provide the skills for improving organization and efficiency in daily tasks. Research has shown that, alongside medication, psychological interventions in adults can be effective in reducing symptomatic deficiencies. Emerging evidence suggests a possible role for cognitive behavioral therapy (CBT) alongside medication in the treatment of adult ADHD. Treatment of ADHD may also include teaching a person mindfulness techniques or meditation. In conjunction with cognitive behavioral therapy these techniques allows a person to learn how to be aware, accept one's own thought and feelings, and improve focus and concentration.
In North America and Europe, it is estimated that three to five percent of adults have ADHD. Of those adults with ADHD an estimated 10% of those have received a formal diagnosis.[non-primary source needed][non-primary source needed] It has been estimated that 5% of the global population has ADHD (including cases not yet diagnosed). In the context of the World Health Organization World Mental Health Survey Initiative, researchers screened more than 11,000 people aged 18 to 44 years in ten countries in the Americas, Europe and the Middle East. On this basis they estimated the adult ADHD proportion of the population to average 3.5 percent with a range of 1.2 to 7.3 percent, with a significantly lower prevalence in low-income countries (1.9%) compared to high-income countries (4.2%). The researchers concluded that adult ADHD often co-occurs with other disorders, and that it is associated with considerable role disability. Although they found that few adults are treated for ADHD itself, in many instances treatment is given for the co-occurring disorders.[non-primary source needed]
Early work on disorders of attention was conducted by Alexander Crichton in 1798 writing about "mental restlessness". The underlying condition came to be recognized from the early 1900s by Sir George Still. Efficacy of medications on symptoms was discovered during the 1930s and research continued throughout the twentieth century. ADHD in adults began to be studied from the early 1970s and research has increased as worldwide interest in the condition has grown.
In the 1970s researchers began to realize that the condition now known as ADHD did not always disappear in adolescence, as was once thought. The expansion of the definition for ADHD beyond only being a condition experienced by children was mainly accomplished by refocusing the diagnosis on inattention instead of hyperactivity. At about the same time, some of the symptoms were also noted in many parents of the children under treatment. The condition was formally recognized as affecting adults in 1978, often informally called adult ADD, since symptoms associated with hyperactivity are generally less pronounced.[unreliable medical source]
Society and cultureEdit
ADHD in adults, as with children, is recognized as an impairment that may constitute a disability under U.S. federal disability nondiscrimination laws, including such laws as the Rehabilitation Act of 1973 and the Americans With Disabilities Act (ADA, 2008 revision), if the disorder substantially limits one or more of an individual's major life activities. For adults whose ADHD does constitute a disability, workplaces have a duty to provide reasonable accommodations, and educational institutions have a duty to provide appropriate academic adjustments or modifications, to help the individual work more efficiently and productively.
In a 2004 study it was estimated that the yearly income discrepancy for adults with ADHD was $10,791 less per year than high school graduate counterparts and $4,334 lower for college graduate counterparts. The study estimates a total loss in productivity in the United States of over $77 billion USD. By contrast, loss estimations are $58 billion for non-alcoholic substance abuse, $85 billion for excessive alcohol use and $43 billion for depression.[unreliable medical source]
ADHD controversies include concerns about its existence as a disorder, its causes, the methods by which ADHD is diagnosed and treated including the use of stimulant medications in children, possible overdiagnosis, misdiagnosis as ADHD leading to undertreatment of the real underlying disease, alleged hegemonic practices of the American Psychiatric Association and negative stereotypes of children diagnosed with ADHD. These controversies have surrounded the subject since at least the 1970s.
- Zametkin AJ, Nordahl TE, Gross M, King AC, Semple WE, Rumsey J, et al. (November 1990). "Cerebral glucose metabolism in adults with hyperactivity of childhood onset". The New England Journal of Medicine. 323 (20): 1361–6. doi:10.1056/nejm199011153232001. PMID 2233902.
- Anastopoulos AD, Shelton TL (31 May 2001). Assessing attention-deficit/hyperactivity disorder. Topics in Social Psychiatry. New York: Kluwer Academic/Plenum Publishers. ISBN 978-0-306-46388-4. OCLC 51784126.
- Hechtman L (8 February 2009). "ADHD in Adults". In Brown TE (ed.). ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults (1st ed.). Washington, DC: American Psychiatric Publishing. p. 87. ISBN 9781585628339. OCLC 701833161.
- Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. (September 2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry. 10: 67. doi:10.1186/1471-244X-10-67. PMC 2942810. PMID 20815868.
- Kooij JJ, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. (February 2019). "Updated European Consensus Statement on diagnosis and treatment of adult ADHD". European Psychiatry. 56: 14–34. doi:10.1016/j.eurpsy.2018.11.001. PMID 30453134.
- "Attention Deficit Hyperactivity Disorder: ADHD in Adults". WebMD.
- ADDitude Magazine; - Attention Deficit > ADD Symptoms & Statistics Is it ADHD? Checklist of 18 ADHD Symptoms Do you have ADD?
- Gentile JP, Atiq R, Gillig PM (August 2006). "Adult ADHD: Diagnosis, Differential Diagnosis, and Medication Management". Psychiatry. 3 (8): 25–30. PMC 2957278. PMID 20963192.
- Palmini A (2008). "Professionally successful adults with attention-deficit/hyperactivity disorder (ADHD): Compensation strategies and subjective effects of pharmacological treatment". Dementia & Neuropsychologia. 2 (1): 63–70. doi:10.1590/S1980-57642009DN20100013. PMC 5619157. PMID 29213543.
- Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE (July 2000). "Attention-deficit/hyperactivity disorder in adults: an overview". Biological Psychiatry. 48 (1): 9–20. doi:10.1016/S0006-3223(00)00889-1. PMID 10913503. S2CID 15987079.
- DuPaul GJ (2004). "ADHD Identification and Assessment: Basic Guidelines for Educators" (PDF). In Canter AS, Paige LZ, Roth MD, Romero I, Carroll SA (eds.). Helping Children at Home and School II: Handouts for Families and Educators. Bethesda, MD: NASP Publications. pp. S8–17–S8–19. ISBN 978-0-932955-82-1.
- Rettew DC, Hudziak JJ (2009). "Genetics of ADHD". In Brown TE (ed.). ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults (1st ed.). Washington, DC: American Psychiatric Publishing. p. 32. ISBN 978-1-58562-158-3. OCLC 244601824.
- Asherson P, Agnew-Blais J (2019). "Annual Research Review: Does late-onset attention-deficit/hyperactivity disorder exist?". J Child Psychol Psychiatry. 60 (4): 333–352. doi:10.1111/jcpp.13020. PMID 30843223.
- "NIMH » Could I Have Attention-Deficit/Hyperactivity Disorder (ADHD)?". www.nimh.nih.gov. Retrieved 2019-11-20.
- CDC (2019-10-08). "Treatment of ADHD". Centers for Disease Control and Prevention. Retrieved 2019-11-20.
- Bjerrum MB, Pedersen PU, Larsen P (April 2017). "Living with symptoms of attention deficit hyperactivity disorder in adulthood: a systematic review of qualitative evidence". JBI Database of Systematic Reviews and Implementation Reports. 15 (4): 1080–1153. doi:10.11124/JBISRIR-2017-003357. PMID 28398986. S2CID 35553368.
- Curatolo P, D'Agati E, Moavero R (December 2010). "The neurobiological basis of ADHD". Italian Journal of Pediatrics. 36 (1): 79. doi:10.1186/1824-7288-36-79. PMC 3016271. PMID 21176172.
- Division of Human Development, National Center on Birth Defects and Developmental Disabilities (29 September 2014). "Attention-Deficit / Hyperactivity Disorder (ADHD): Symptoms and Diagnosis". Centers for Disease Control and Prevention.
- Valdizán JR, Izaguerri-Gracia AC (February 2009). "[Attention deficit hyperactivity disorder in adults]" [Attention deficit hyperactivity disorder in adults]. Revista de Neurologia (in Spanish). 48 Suppl 2 (Suppl 2): S95-9. PMID 19280582.
- Hollis, Chris (June 2018). "ADHD and transitions to adult mental health services". Oxford Medicine Online. doi:10.1093/med/9780198739258.003.0043.
- Stanford C, Tannock R (29 February 2012). Behavioral Neurobiology of Attention Deficit Hyperactivity Disorder and Its Treatment. Springer. pp. 10–. ISBN 978-3-642-24611-1.
- Katragadda S, Schubiner H (June 2007). "ADHD in children, adolescents, and adults". Primary Care. 34 (2): 317–41, abstract viii. doi:10.1016/j.pop.2007.04.012. PMID 17666230.
- Eden GF, Vaidya CJ (December 2008). "ADHD and developmental dyslexia: two pathways leading to impaired learning". Annals of the New York Academy of Sciences. 1145: 316–27. doi:10.1196/annals.1416.022. PMID 19076406. S2CID 45481868.
- McKeague L, Hennessy E, O'Driscoll C, Heary C (June 2015). "Retrospective accounts of self-stigma experienced by young people with attention-deficit/hyperactivity disorder (ADHD) or depression". Psychiatric Rehabilitation Journal. 38 (2): 158–163. doi:10.1037/prj0000121. PMID 25799297.
- Derrer D. "Conditions Similar to ADHD". WebMD. WebMD. Retrieved 16 October 2015.
- "Diagnosis of ADHD in Adults". CHADD. Retrieved 2019-11-20.
- Hodgkins P, Arnold LE, Shaw M, Caci H, Kahle J, Woods AG, Young S (18 January 2012). "A systematic review of global publication trends regarding long-term outcomes of ADHD". Frontiers in Psychiatry. 2: 84. doi:10.3389/fpsyt.2011.00084. PMC 3260478. PMID 22279437.
- Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV (June 2011). "Advances in understanding and treating ADHD". BMC Medicine. 9: 72. doi:10.1186/1741-7015-9-72. PMC 3126733. PMID 21658285.
- Madras BK, Miller GM, Fischman AJ (March 2002). "The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD)". Behavioural Brain Research. 130 (1–2): 57–63. doi:10.1016/S0166-4328(01)00439-9. PMID 11864718. S2CID 6512707.
- Bannon MJ (May 2005). "The dopamine transporter: role in neurotoxicity and human disease". Toxicology and Applied Pharmacology. 204 (3): 355–60. doi:10.1016/j.taap.2004.08.013. PMID 15845424.
- Schweitzer JB, Hanford RB, Medoff DR (December 2006). "Working memory deficits in adults with ADHD: is there evidence for subtype differences?". Behavioral and Brain Functions. 2: 43. doi:10.1186/1744-9081-2-43. PMC 1762010. PMID 17173676.
- Kim S, Liu Z, Glizer D, Tannock R, Woltering S (August 2014). "Adult ADHD and working memory: neural evidence of impaired encoding". Clinical Neurophysiology. 125 (8): 1596–603. doi:10.1016/j.clinph.2013.12.094. PMID 24411642. S2CID 25814844.
- Missonnier P, Hasler R, Perroud N, Herrmann FR, Millet P, Richiardi J, et al. (June 2013). "EEG anomalies in adult ADHD subjects performing a working memory task". Neuroscience. 241: 135–46. doi:10.1016/j.neuroscience.2013.03.011. PMID 23518223. S2CID 937794.
- Kubose S (February 2000). "ADHD in Adults: Are the current Diagnostic Criteria Adequate?". NeuroPsychiatry Reviews. 1 (1). Archived from the original on 2008-09-21. Retrieved 2008-10-01.
- Moon KF (2004). "Development of the DSM". The History of Psychiatric Classification: From Ancient Egypt to Modern America (A Website composed for the History of Psychology (PSYC 6180) The University of Georgia). Archived from the original on 6 June 2009.
- Kieling C, Kieling RR, Rohde LA, Frick PJ, Moffitt T, Nigg JT, et al. (January 2010). "The age at onset of attention deficit hyperactivity disorder". The American Journal of Psychiatry. 167 (1): 14–6. doi:10.1176/appi.ajp.2009.09060796. PMC 4478075. PMID 20068122.
- "314.0x Attention Deficit/Hyperactivity Disorder: Proposed Revision". DSM-5 Development. American Psychiatric Association. 20 May 2010. Archived from the original on 4 December 2010.
- Moffitt TE, Houts R, Asherson P, Belsky DW, Corcoran DL, Hammerle M; et al. (2015). "Is Adult ADHD a Childhood-Onset Neurodevelopmental Disorder? Evidence From a Four-Decade Longitudinal Cohort Study". Am J Psychiatry. 172 (10): 967–77. doi:10.1176/appi.ajp.2015.14101266. PMC 4591104. PMID 25998281.CS1 maint: multiple names: authors list (link)
- Faraone SV, Biederman J (September 2002). "Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis". Journal of Attention Disorders. 6 (2): 69–75. doi:10.1177/108705470200600203. PMID 12142863. S2CID 33187299.
- Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, et al. (2020-10-21). "Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis". PLOS ONE. 15 (10): e0240584. doi:10.1371/journal.pone.0240584. PMC 7577505. PMID 33085721.
- Searight HR, Burke JM, Rottnek F (November 2000). "Adult ADHD: evaluation and treatment in family medicine". American Family Physician. 62 (9): 2077–86, 2091–2. PMID 11087189.
- Retz W, Retz-Junginger P, Thome J, Rösler M (September 2011). "Pharmacological treatment of adult ADHD in Europe". The World Journal of Biological Psychiatry. 12 Suppl 1: 89–94. doi:10.3109/15622975.2011.603229. PMID 21906003. S2CID 34871481.
- "Canadian ADHD Practice Guidelines | CADDRA". Retrieved 2020-10-24.
- Godfrey J (March 2009). "Safety of therapeutic methylphenidate in adults: a systematic review of the evidence". Journal of Psychopharmacology. 23 (2): 194–205. doi:10.1177/0269881108089809. PMID 18515459. S2CID 5390805.
- Bolea-Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. (March 2014). "Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 28 (3): 179–203. doi:10.1177/0269881113519509. PMID 24526134. S2CID 28503360.
- Simpson D, Plosker GL (2004). "Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder". CNS Drugs. 18 (6): 397–401. doi:10.2165/00023210-200418060-00011. PMID 15089111. S2CID 23171429.
- Santosh PJ, Sattar S, Canagaratnam M (September 2011). "Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults". CNS Drugs. 25 (9): 737–63. doi:10.2165/11593070-000000000-00000. PMID 21870887. S2CID 207300617.
- Wilens TE, Morrison NR, Prince J (October 2011). "An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults". Expert Review of Neurotherapeutics. 11 (10): 1443–65. doi:10.1586/ern.11.137. PMC 3229037. PMID 21955201.
- Verbeeck W, Tuinier S, Bekkering GE (February 2009). "Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review". Advances in Therapy. 26 (2): 170–84. doi:10.1007/s12325-009-0008-7. PMID 19238340. S2CID 5975939.
- "NIMH » Attention-Deficit/Hyperactivity Disorder". www.nimh.nih.gov. Retrieved 2019-11-20.
- Rösler M, Casas M, Konofal E, Buitelaar J (August 2010). "Attention deficit hyperactivity disorder in adults". The World Journal of Biological Psychiatry. 11 (5): 684–98. doi:10.3109/15622975.2010.483249. PMID 20521876. S2CID 25802733.
- Knouse LE, Safren SA (September 2010). "Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder". The Psychiatric Clinics of North America. 33 (3): 497–509. doi:10.1016/j.psc.2010.04.001. PMC 2909688. PMID 20599129.
- de Graaf R, Kessler RC, Fayyad J, ten Have M, Alonso J, Angermeyer M, et al. (December 2008). "The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative". Occupational and Environmental Medicine. 65 (12): 835–42. doi:10.1136/oem.2007.038448. PMC 2665789. PMID 18505771.
- Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. (April 2006). "The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication". The American Journal of Psychiatry. 163 (4): 716–23. doi:10.1176/appi.ajp.163.4.716. PMC 2859678. PMID 16585449.
- Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (June 2007). "The worldwide prevalence of ADHD: a systematic review and metaregression analysis". The American Journal of Psychiatry. 164 (6): 942–8. doi:10.1176/appi.ajp.164.6.942. PMID 17541055.
- Willcutt EG (July 2012). "The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review". Neurotherapeutics. 9 (3): 490–9. doi:10.1007/s13311-012-0135-8. PMC 3441936. PMID 22976615.
- Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. (May 2007). "Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder". The British Journal of Psychiatry. 190 (5): 402–9. doi:10.1192/bjp.bp.106.034389. PMID 17470954.
- Berrios GE (December 2006). "'Mind in general' by Sir Alexander Crichton" (PDF). History of Psychiatry. 17 (68 Pt 4): 469–86. doi:10.1177/0957154x06071679. PMID 17333675. S2CID 6101515.
- Lange KW, Reichl S, Lange KM, Tucha L, Tucha O (December 2010). "The history of attention deficit hyperactivity disorder". Attention Deficit and Hyperactivity Disorders. 2 (4): 241–55. doi:10.1007/s12402-010-0045-8. PMC 3000907. PMID 21258430.
- Ryan N, McDougall T (2009). Nursing Children and Young People with ADHD. Taylor & Francis. p. 6. ISBN 9781134052196.
- Conrad P (2007). The Medicalization of Society. Baltimore, Maryland: Johns Hopkins University Press. pp. 66. ISBN 978-0801885853.
- Barkley, R. A., Murphy, K. R., & Fischer, M. (2008). ADHD in adults : what the science says. Guilford Press.
- "Adult ADHD Help Near Fort Worth, Texas". Dr. Lisa Fairweather. Fairweather Medical Group in Colleyville, Texas. Retrieved 27 October 2014.
- ADA Division, Office of Legal Counsel (22 October 2002). "Enforcement Guidance: Reasonable Accommodation and Undue Hardship Under the Americans with Disabilities Act". The U.S. Equal Employment Opportunity Commission.
- Office of Civil Rights (25 June 2012). "Questions and Answers on Disability Discrimination under Section 504 and Title II". U.S. Department of Education.
- "Breaking News: The Social and Economic Impact of ADHD". American Medical Association. 7 September 2004. Archived from the original on 22 October 2004.
- Reinberg S (9 September 2004). "Adult ADHD Costs Billions in Lost Income". HealingWell.
- Cormier E (October 2008). "Attention deficit/hyperactivity disorder: a review and update". Journal of Pediatric Nursing. 23 (5): 345–57. doi:10.1016/j.pedn.2008.01.003. PMID 18804015.